pomalidomide

Also known as CC-4047, IMID-3, Imnovid®, Pomalyst®, CC 4047, 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide, 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione, 4-Aminothalidomide

Pomalidomide, sold under the brand name Pomalyst among others, is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. It inhibits angiogenesis, the formation of new blood vessels.

Key facts

Drug.width: 200
Drug.image: Pomalidomide enantiomers.svg
Drug.image_class: skin-invert-image
Drug.chirality: Racemic mixture
Drug.tradename: Pomalyst, others
Drug.MedlinePlus: a613030
Drug.DailyMedID: Pomalidomide
Drug.pregnancy_AU: X
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: L04
Drug.ATC_suffix: AX06
Drug.legal_AU: S4
Drug.legal_BR: C3
Drug.legal_CA: Rx-only
Drug.legal_UK: POM
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only
Drug.bioavailability: 73% (at least)

via Wikipedia infobox

Chemical data

Formula: C13H11N3O4
Molecular weight: 273.24 g/mol
IUPAC name: 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
InChIKey: UVSMNLNDYGZFPF-UHFFFAOYSA-N
XLogP: 0.2
Polar surface area: 110 Å²
H-bond donors: 2
H-bond acceptors: 5
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 2013
Admin. routes: oral
Indications: myeloproliferative disorder, immune system disease, systemic scleroderma, multiple myeloma

via ChEMBL · EBI

Research

1,522 papers

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.The Lancet. Oncology · 2021
Pomalidomide.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2014
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.The New England journal of medicine · 2024
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.Lancet (London, England) · 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.The Lancet. Oncology · 2019

via PubMed

Wikidata facts

Subclass of: chemical compound
Mass: 273.074956
Has use: medication

Show 6 more facts

defined daily dose: 3
chemical formula: C₁₃H₁₁N₃O₄
Commons category: Pomalidomide
canonical SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
World Health Organisation international non-proprietary name: pomalidomide
subject has role: angiogenesis inhibitor

Sources (5)

via Wikidata · CC0

~3 min read

Encyclopedic overview

7 sections

Contents

Medical uses
Side effects
Pharmacology
Mechanism of action
History
Clinical trials
References

Pomalidomide was approved for medical use in the United States in February 2013, and in the European Union in August 2013. It is available as a generic medication.

Excerpted from Wikipedia’s “pomalidomide” article, available under the CC BY-SA 4.0 licence.

Available in 14 languages

via Wikidata sitelinks · CC0